| Date | Title | Description |
| 26.03.2021 | Chime Biologics Announced the Completion of $190 Million Series A+ Financing to Accelerate Capacity Expansion | March 26, 2021, Wuhan - Chime Biologics, a China-based, world-class CDMO company, announced today that it has secured a total commitment of $190 million Series A+ investment from institutional investors in which over $100 million investment... |
| 08.04.2020 | Chime Biologics Has Signed a Contract with Wuhan East Lake High-Tech Zone of Investing $900 Million to Build the World's Most Competitive Biomedical CDMO Commercial Base | WUHAN, Apr. 8, 2020 — Chime Biologics, formerly “Xikang (Wuhan) biopharmaceutical Co., Ltd.”, today participated the special event of Wuhan “Cloud Investment” hosted by Wuhan Municipal People’s Government. Witnessed by Provincial, municipal... |
| 10.03.2020 | Chime Biologics Is Evolving into One of the Leading CDMOs in China Serving the Global Biotech Industry | Wuhan, China, March 10, 2020 – Chime Biologics, a China-based, world-class Contract Development and Manufacturing Organization (CDMO) providing fully-integrated services to support development and manufacturing of complex biologics, today a... |
| 26.02.2020 | JHL Biotech Focuses on CDMO and Biologics Development for Global Markets After Spinoff | HSINCHU, Taiwan, February 26, 2020 — With a globally-focused enthusiasm and aspiration to build sustainable and reputable CDMO facilities for the China Biologics Market, JHL Biotech has made a strategic decision benefitting all of its patie... |
| 13.01.2020 | CredSimple Acquires Glenridge Health to Build the Industry's Most Comprehensive End-to-End Provider Network Management Solution | Strategic acquisition will streamline services, control costs, and ensure compliance |
| 16.08.2019 | JHL Focusing on New Biosimilar Pipeline and Global Expansion of CDMO Business | HSINCHU, Taiwan and WUHAN, China, August 16, 2019 — JHL Biotech has reached a settlement agreement with Genentech to resolve Genentech’s civil claims related to the development of certain biologic therapies, or “biosimilar” medicines. After... |
| 01.04.2019 | FDA Approves ASCENIV™, a Novel Intravenous Immune Globulin | RAMSEY, N.J. and BOCA RATON, Fla., April 01, 2019 (GLOBE NEWSWIRE) - ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures,... |
| 06.10.2018 | Strand Life Sciences Acquires India Diagnostics Business From Quest Diagnostics | October 6, 2018 | Bangalore |
| 26.07.2018 | ADMA Biologics Reports Successful Close-Out of Its April 2018 FDA Compliance Inspection | RAMSEY, N.J. and BOCA RATON, Fla., July 26, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that manufactures, markets and develops specialt... |
| 18.06.2018 | Quest Analytics Acquires BetterDoctor | [Appleton, WI] – [June 18, 2018] – Quest Analytics, the leading provider of network access and adequacy services to health plans and insurance regulatory agencies, today announced that it has acquired BetterDoctor, the nation’s most accurat... |
| 22.01.2018 | Celgene Corporation to Acquire Juno Therapeutics | |
| 21.12.2017 | JHL Biotech Submits Clinical Trial Application in Europe for Proposed Dornase Alfa Biosimilar to Affordably Manage Symptoms of Cystic Fibrosis | HSINCHU, Taiwan and WUHAN, China, December 21, 2017 - JHL Biotech Inc. (Stock Code: 6540.TWO) announced today that it has submitted a Phase 1 Clinical Trial Application to the Dutch Healthcare Authority for its proposed dornase alfa biosimi... |
| 18.12.2017 | JHL Submits Clinical Trial Application for Proposed Bevacizumab Biosimilar | JHL Biotech, at December 15, 2017, has submitted a Phase I Clinical Trial Application (“CTA”) to European authorities for its proposed bevacizumab biosimilar, JHL1149. |
| 06.06.2017 | ADMA Biologics Completes Acquisition of Biotest's Therapy Business Unit Assets | Transaction Creates Vertically Integrated Commercial Plasma Products Company |
| 05.04.2017 | China FDA Accepts JHL’s First Clinical Trial Application | Wuhan, China and Hsinchu, Taiwan - JHL Biotech Inc. (Stock Code: 6540.TWO) is announcing that its Clinical Trial Application (“CTA”) for use of JHL1101 in Phase 1 and Phase 3 clinical trials in Non-Hodgkin’s Lymphoma patients has been accep... |
| 29.03.2017 | JHL Doses First Patient In JHL1101 Phase I European Trial | JHL Biotech Inc. (Stock Code: 6540.TWO) today announced that the first patient has been dosed in the company's Phase I clinical trial of JHL1101 (a proposed rituximab biosimilar) in rheumatoid arthritis patients. |
| 10.01.2017 | HyperMed Imaging, Inc. Receives FDA Clearance for Its New HyperView™ Product | HyperMed Imaging, Inc. announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for the company’s new medical imaging device called HyperView™. The HyperView product is a handheld, battery operated, po... |
| 05.12.2016 | Sanofi and JHL Biotech Announce Strategic Biologics Alliance in China | Shanghai, China - 5 December 2016 – Sanofi (EURONEXT: SAN and NYSE: SNY), a global healthcare leader and JHL Biotech, Inc. (6540.TWO), a biopharmaceutical company with development and manufacturing facilities in Wuhan and Taiwan, announced ... |
| 27.07.2016 | Scientific Publication by a Group Including Juno Therapeutics Scientific Co-Founder Michel Sadelain Is Featured in Endpoints News Article | by John Carroll
July 26, 2016 |
| 25.02.2016 | JHL Biotech Announces Mechanical Completion of its Wuhan Biopharmaceutical Manufacturing Facility | Wuhan, China and Amersham, UK; 25 February 2016: JHL Biotech (TWEM: 6540) and GE Healthcare’s Life Sciences business (NYSE: GE) are proud to announce mechanical completion of JHL Biotech’s JHL-1 biopharmaceutical manufacturing facility in t... |
| 27.01.2016 | Venaxis Announces Transaction with Strand Life Sciences | CASTLE ROCK, Colo., January 26, 2016 /PRNewswire/ - Venaxis®, Inc. (Nasdaq: APPY), announced today that it has entered into a series of agreements for a transaction with Strand Life Sciences Private Limited (Strand LS) and its shareholders.... |
| 03.11.2015 | JHL Biotech Intends to Manufacture Biosimilars in Its New Facility, the Company Is Featured in Fierce Pharma Manufacturing and Bloomberg Articles | JHL Biotech intends to manufacture biosimilars in its new facility |
| 05.10.2015 | Strand Life Sciences Is Featured in GenomeWeb Article | Oct 05, 2015 |
| 02.10.2015 | JHL Biotech Lists on the Taiwan Emerging Stock Board | HSINCHU, TAIWAN – October 2, 2015—JHL Biotech (TWEM: 6540), an emerging biosimilars company incorporated in Cayman Islands and based in Taiwan and China, announced today it has been publicly listed on the Taiwan Emerging Stock Board, effect... |
| 21.09.2015 | FDA Accepts ADMA Biologics License Application for RI-002 | RAMSEY, N.J., Sept. 21, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics, announced that the U.S. ... |
| 13.05.2015 | JHL Biotech Successfully Raises $45.6 Million Series C Financing | HSINCHU, TAIWAN – May 11, 2015 – JHL Biotech, Inc., an emerging biopharmaceutical company, today announced that it has closed a Series C fundraising of $45.6 million, led by funds managed by a global renowned crossover fund with over US$1.6... |
| 18.12.2014 | Juno Therapeutics Announces Pricing of Initial Public Offering | December 18, 2014 06:14 PM Eastern Standard Time |
| 05.12.2014 | Opus Bio to License CD22 CAR T Cell Technology to Juno | GREENWICH, CT (December 5, 2014) - Opus Bio, Inc., today announced that Juno Therapeutics, Inc. has entered into an agreement to obtain a license for the company’s CAR-T cell product candidate targeting CD22, a protein expressed on most B c... |
| 03.12.2014 | ADMA Biologics Announces Positive Top-Line Phase III Data for Primary Immune Deficiency Disease (PIDD) Patients | RAMSEY, N.J., Dec. 3, 2014 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention o... |
| 05.11.2014 | ADMA Biologics Approved for Trading on NASDAQ | RAMSEY, N.J., Nov. 5, 2014 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of... |
| 27.08.2014 | Alcon to Acquire WaveTec® Vision, Developer of First Commercialized Intra-Operative Guidance System for Enhanced Cataract Outcomes | Fort Worth, Texas, Aug. 27, 2014 - Alcon, the global leader in eye care and the second largest division of Novartis Group, announced today that the company has entered into an agreement to acquire WaveTec® Vision, a privately-held company t... |
| 14.08.2014 | Lentigen Corporation Announces Sale of Lentiviral Vector Manufacturing Business and Change of Name to Opus Bio, Inc. | |
| 09.05.2014 | Launch of The Strand Triesta Center for Cancer Genomics | - |
| 08.05.2014 | HCG Announces New Standard-of-Care for Cancer Treatment in India | - |
| 17.12.2013 | Curie-Cancer and Strand Launch Curie Image Database | PARIS and SAN FRANCISCO, December 17, 2013 /PRNewswire/ -- |
| 05.12.2013 | Strand Life Sciences to Partner with US Based El Camino Hospital to Set Up Strand Center for Genomics and Personalized Medicine | BANGALORE, India, December 5, 2013 /PRNewswire/ -- |
| 18.11.2013 | Why Strand Life Sciences Wants Doctors to Genetically Profile Patients | Seema Singh | Forbes India |
| 18.11.2013 | Strand launches Early Access Program for Clinical Genomics Interpretation and Reporting Platform | - |
| 22.10.2013 | BetterDoctor Raises $2.6 Million to Alleviate the Pain of Finding a Good Doctor | CHRISTINA FARR OCTOBER 22, 2013 1:12 PM |
| 17.10.2013 | ADMA Biologics Announces Pricing of Initial Public Offering | RAMSEY, N.J.--ADMA Biologics, Inc. (OTCQB: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, to... |
| 25.09.2013 | GE Healthcare Life Sciences to Build KUBio Modular Biopharmaceutical Factory for JHL Biotech in China | New factory to give JHL Biotech commercial biopharmaceutical manufacturing capabilities in Asia |
| 24.09.2013 | Pancreatic Cancer Imaging Agent Earns MabVax $1.75 Million SBIR Award | MabVax Therapeutics has received a contract from the National Cancer Institute under the Small Business Innovation Research Technology Program (SBIR). The award is in the amount of $1,750,000 over the next three years and will support devel... |
| 06.09.2013 | WhiteGlove Health Names New Chief Executive Officer | AUSTIN, Texas--(BUSINESS WIRE)--WhiteGlove Health, (WGH) a leading service driven and outcomes-oriented healthcare provider, focusing on enhancing quality and improving the consumers’ healthcare experience while lowering the cost, today ann... |
| 13.05.2013 | JHL Biotech Partners With GE Healthcare Life Sciences to Build Monoclonal Antibody Manufacturing Plant | On March 13, 2013, leaders from JHL Biotech and GE Healthcare Life Sciences signed a strategic cooperation agreement. The two companies will build a monoclonal antibody manufacturing plant in Wuhan’s Biolake Science Park. Many executives fr... |
| 12.03.2013 | Cordis Acquires Flexible Stenting Solutions, a Biomark Capital Fund IV Portfolio Company | Agreement Expands Treatment Options for Advanced Peripheral Artery Disease |
| 13.02.2013 | Lentigen Receives U.S. Orphan Drug Designation For Novel Gene Therapy For Glioblastoma Multiforme | GAITHERSBURG, Md., Feb. 13, 2013 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced today that that the U.S. Food and Drug Administra... |
| 11.02.2013 | Strand Life Sciences raises Series B Round | BANGALORE, February 11, 2013 /PRNewswire/ -- |
| 21.11.2012 | MabVax Therapeutics Secures First Series B Tranche | 11/21/2012 - 1:29PM |
| 14.11.2011 | Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer | CLEVELAND - University Hospitals (UH) Case Medical Center, Case Western Reserve University School of Medicine and Lentigen Corporation announced today the initiation of a novel Phase I clinical trial of LG631 gene therapy for the protection... |